Invectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients. This represents a great improvement for patient care as administration by Tropis is easy to perform, reliable and precise. Moreover, this system is cost-effective and brings increased comfort for patients with lower pain and better local tolerance (compared to electroporation).”
Cancer incidence and mortality are rapidly growing worldwide. In 2018 there were an estimated 18.1 million new cases and 9.6 million deaths. In addition, there were 43.8 million persons living with cancer who were diagnosed within the last 5 years. Based on projected population aging and growth, the global burden of cancer is set to increase by more than 60% by 2040, to a predicted 29.4 million cases. (1)
To learn more, please refer to the study published in Clinical Cancer Research on November 19, 2019.
1 American Cancer Society. The Cancer Burden, The Cancer Atlas. 2019. https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/